This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| sTRX4 | |
|---|---|
| Name | sTRX4 |
sTRX4 sTRX4 is described in the literature as a proteinaceous factor implicated in redox regulation and signal transduction. It has been investigated across biochemical, clinical, and epidemiological studies linking it to oxidative stress, inflammatory pathways, and several human diseases. Research on sTRX4 spans biochemical characterization, biomarker development, and therapeutic targeting.
sTRX4 has been characterized in comparative studies alongside Thioredoxin, Glutaredoxin, Peroxiredoxin, Superoxide dismutase, and Catalase to define its role in cellular redox homeostasis. Structural biology efforts referenced methods developed in studies of X-ray crystallography applied to proteins such as Hemoglobin, Myoglobin, and Ribonuclease A while drawing on paradigms from Protein Data Bank submissions. Functional assays have been compared to classical investigations of p53, NF-κB, MAPK1, AKT1, and Nrf2 signaling axes in mammalian cells.
Biochemical analyses report that sTRX4 contains conserved motifs analogous to active sites described in Thioredoxin fold proteins and shares mechanistic features with Glutathione reductase and enzymes like Thioredoxin peroxidase. High-resolution techniques that mapped its tertiary fold referenced protocols used in solving structures of Lysozyme, DNA polymerase I, Cytochrome c, and Catalase. Functional experiments placed sTRX4 activity within pathways involving KEAP1, ARE-binding proteins, AP-1, STAT3, and HIF-1α, suggesting modulatory effects on post-translational modifications characterized in studies of SUMO1, Ubiquitin, SMAD3, and CREB1.
Clinically, altered sTRX4 expression has been correlated with disease phenotypes similar to those explored for Alzheimer's disease, Parkinson's disease, Type 2 diabetes mellitus, Coronary artery disease, and Rheumatoid arthritis. Biomarker panels including sTRX4 were evaluated alongside established markers such as C-reactive protein, Interleukin-6, Tumor necrosis factor-alpha, Brain-derived neurotrophic factor, and Procalcitonin to stratify risk and prognosis. Studies leveraging cohorts from consortia like UK Biobank, Framingham Heart Study, Nurses' Health Study, and The Rotterdam Study explored associations with outcomes studied in World Health Organization reports and guidelines from agencies like Centers for Disease Control and Prevention.
Detection methods for sTRX4 have adapted platforms validated for proteins such as Interleukin-8, Troponin I, Prostate-specific antigen, HER2, and CEA. Techniques include enzyme-linked assays inspired by protocols used for ELISA development in diagnostics of HIV, Hepatitis C virus, and SARS-CoV-2 serology, mass spectrometry pipelines paralleling analyses of β-amyloid, Tau protein, and Alpha-synuclein, and imaging adjuncts referenced in studies of Positron emission tomography, Magnetic resonance imaging, and Computed tomography for phenotypic correlation. Quality control and standardization efforts referenced frameworks established by Clinical and Laboratory Standards Institute and regulatory filings with Food and Drug Administration.
Therapeutic strategies targeting sTRX4 draw on approaches used for modulating proteins such as BRAF, EGFR, PD-1, CTLA-4, and TNF including small molecules, monoclonal antibodies, and nucleic acid therapeutics. Preclinical models employed transgenic and knockout approaches analogous to those used in studies of p53-knockout mouse, ApoE-deficient mouse, NOD mouse, and Zebrafish models for drug discovery pipelines like those used by NIH, GSK, Pfizer, Roche, and Novartis. Clinical translation efforts reference trial designs and endpoints similar to randomized studies overseen by European Medicines Agency and multicenter trials coordinated by networks such as ASCO and NCI cooperative groups.
Population-level investigations of sTRX4 frequency and associations utilized methodologies established in population genetics and epidemiology literature exemplified by studies of BRCA1, APOE, HLA-B27, CFTR, and KRAS. Geographic and demographic analyses invoked datasets from Human Genome Project resources, 1000 Genomes Project, and national health surveys like NHANES to evaluate distribution patterns, co-morbid associations studied in Global Burden of Disease Study, and environmental interactions paralleling analyses in INTERHEART and EPIC cohorts.
The discovery narrative for sTRX4 parallels canonical descriptions of novel proteins in the late 20th and early 21st centuries, referencing methodological milestones exemplified by the identification of Insulin, Interferon, Epidermal growth factor, Interleukin-2, and Transforming growth factor beta. Nomenclature discussions referenced conventions from HUGO Gene Nomenclature Committee and historical naming precedents set in studies of Myc, Ras, Src, and Jun.
Category:Proteins